Letrozole ( DrugBank: Letrozole )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 81 | 先天性副腎皮質酵素欠損症 | 1 |
| 89 | リンパ脈管筋腫症 | 1 |
81. 先天性副腎皮質酵素欠損症
臨床試験数 : 88 / 薬物数 : 90 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001521 (ClinicalTrials.gov) | June 8, 1995 | 3/11/1999 | Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia | An Open, Randomized, Long-Term Clinical Trial of Flutamide, Testolactone, and Reduced Hydrocortisone Dose vs. Conventional Treatment of Children With Congenital Adrenal Hyperplasia | Congenital Adrenal Hyperplasia (CAH) | Drug: Flutamide;Drug: Letrozole;Drug: Hydrocortisone;Drug: Fludrocortisone | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Active, not recruiting | 2 Years | 18 Years | All | 62 | Phase 2 | United States |
89. リンパ脈管筋腫症
臨床試験数 : 39 / 薬物数 : 46 - (DrugBank : 20) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01353209 (ClinicalTrials.gov) | May 2011 | 11/5/2011 | Trial of Aromatase Inhibition in Lymphangioleiomyomatosis | A TRIAL OF LETROZOLE IN PULMONARY LYMPHANGIOLEIOMYOMATOSIS | Lymphangioleiomyomatosis | Drug: Letrozole;Drug: Placebo | University of Cincinnati | Department of Defense | Completed | 18 Years | N/A | Female | 17 | Phase 2 | United States |